Skip to main content

Table 1 The general clinical data of patients

From: Prospective clinical study of capecitabine plus oxaliplatin concurrent chemoradiotherapy after radical resection of rectal cancer

Information CAPE-OX-CRT group, n = 30 (%) Control group
n = 26 (%)
P
Age (years)
 Median age 58 58  
 Range 27–72 24–73  
Gender 0.432
 Male 13 (43.33) 14 (53.8)  
 Female 17 (56.67) 12 (46.2)  
KPS score 0.240
 70 2 (6) 1 (3.85)  
 80 22 (74) 20 (76.92)  
 90 6 (20) 5 (19.23)  
Postoperative staging 0.890
 II 11 (36.67) 10 (38.46)  
 III 19 (63.33) 16 (61.54)  
Postoperative T staging 0.096
 T2 4 (13.33) 4 (15.38)  
 T3 11 (36.67) 9 (34.62)  
 T4a 12 (40) 10 (38.46)  
 T4b 3 (10) 3 (11.54)  
Postoperative N staging 0.437
 N0 5 (16.67) 6 (23.08)  
 N1 16 (53.33) 12 (46.15)  
 N2 9 (30) 8 (30.77)